Johns Hopkins Scientist Slams Flu Vaccine

A Johns Hopkins scientist has issued a blistering report on influenza vaccines in the British Medical Journal (BMJ). Peter Doshi, Ph.D., charges that although the vaccines are being pushed on the public in unprecedented numbers, they are less effective and cause more side effects than alleged by the Centers for Disease Control and Prevention (CDC). Further, says Doshi, the studies that underlie the CDC’s Flu Shot Sonoran Wellnesspolicy of encouraging most people to get a yearly flu shot are often low quality studies that do not substantiate the official claims.

Promoting influenza vaccines is one of the most visible and aggressive public health policies in the United States, says Doshi of the Johns Hopkins School of Medicine. Drug companies and public officials press for widespread vaccination each fall, offering vaccinations in drugstores and supermarkets. The results have been phenomenal. Only 20 years ago, 32 million doses of influenza vaccine were available in the United States on an annual basis. Today, the total has skyrocketed to 135 million doses.

“The vaccine may be less beneficial and less safe than has been claimed, and the threat of influenza seems to be overstated,” Doshi says. Mandatory vaccination polices have been enacted, often in healthcare facilities, forcing some people to take the vaccine under threat of losing their jobs.

The main assertion of the CDC that fuels the push for flu vaccines each year is that influenza comes with a risk of serious complications which can cause death, especially in senior citizens and those suffering from chronic illnesses. That’s not the case, said Doshi.

When read carefully, the CDC acknowledges that studies finding any perceived reduction in death rates may be due to the “healthy-user effect” — the tendency for healthier people to be vaccinated more than less-healthy people. The only randomized trial of influenza vaccine in older people found no decrease in deaths. “This means that influenza vaccines are approved for use in older people despite any clinical trials demonstrating a reduction in serious outcomes,” says Doshi.”

 

READ MORE HERE!

 

Doshi P. Influenza: marketing vaccine by marketing disease. BMJ. 2013;346:f3037

 

0
  Related Posts

You must be logged in to post a comment.